-- Emyria (ASX:EMD) launched its Empax Global Partnership Program, a services platform allowing international drug sponsors to access the company's clinical delivery infrastructure, according to a Monday filing with the Australian bourse.
The launch establishes a dual-revenue model combining existing reimbursed treatment programs with sponsor-funded services, the filing said.
The company's shares jumped almost 19% in recent Monday trade.